CCM
KRYS icon

Coldstream Capital Management’s Krystal Biotech KRYS Stock Holding History

Coldstream Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-939
Closed -$243K – 1270
2026
Q1 		$243K Buy
939
+16
+2% +$4.26K ﹤0.01% 1041
2025
Q4 		$228K Buy
+923
New +$194K ﹤0.01% 1037
2025
Q2 		– Sell
-556
Closed -$100K – 2297
2025
Q1 		$100K Buy
+556
New +$93.5K ﹤0.01% 1351

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Coldstream Capital Management's KRYS Position: Q2 2026 in Review

Coldstream Capital Management sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 939 shares — an estimated $243K sold.

Coldstream Capital Management first reported a position in KRYS in Q1 2025 and held it in 3 quarters. The position peaked at $243K in Q1 2026. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Coldstream Capital Management reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Coldstream Capital Management sold 939 Krystal Biotech shares in Q2 2026, an estimated $243K.
  • Coldstream Capital Management first reported a position in Krystal Biotech in Q1 2025 and held it in 3 quarters.
  • Coldstream Capital Management's Krystal Biotech position peaked at $243K in Q1 2026.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.